Development Safety Update Report (DSUR)

The DSUR exists because no single trial, country, or year tells the full safety story of an investigational drug. Before ICH E2F, sponsors juggled the FDA IND annual report (21 CFR 312.33), the EU Annual Safety Report, and other country-specific formats with overlapping but non-identical content. ICH E2F, finalized in 2010 and accepted by FDA as guidance in August 2011, harmonized these obligations into a single annual document that pulls together every clinical trial of a given investigational product into one coherent benefit-risk assessment.

The reporting cycle is anchored to the Development International Birth Date (DIBD), defined as the date the sponsor received its first authorization to conduct a clinical trial in any country. The data lock point (DLP) falls on the last day of each 12-month reporting period measured from the DIBD, and the DSUR must reach regulators no later than 60 calendar days after the DLP. The report covers the investigational drug across all indications, dosage forms, and routes of administration globally, including blinded ongoing studies and unblinded data from completed trials.

The ICH E2F structure prescribes specific content: an introduction (identifying the drug, the reporting period, the DIBD, and the report number); worldwide marketing approval status; actions taken for safety reasons (protocol amendments, labeling changes, restrictions, trial suspensions); changes to the reference safety information (the Investigator's Brochure in effect at the start of the period is the baseline for expectedness assessment); inventory of clinical trials; estimated cumulative subject exposure (with methodology and limitations); line listings and summary tabulations; significant findings from clinical trials during the period (serious adverse events, deaths, dose-dependent reactions, laboratory findings); safety findings from non-clinical studies; a literature review; late-breaking information after the DLP; and an overall safety assessment that synthesizes interval and cumulative data into a benefit-risk conclusion. A summary of important risks is included as an appendix under the current format.

The DSUR sits alongside other safety documents but does not replace them. SUSARs (serious unexpected adverse reactions) still require expedited reporting within 7 or 15 calendar days. The Periodic Benefit-Risk Evaluation Report (PBRER), defined under ICH E2C(R2), covers marketed products post-authorization rather than investigational use. In the United States, FDA has accepted an ICH E2F DSUR in place of the IND annual report since 2011, although 21 CFR 312.33 remains the standing regulatory text; a proposed rule (RIN 0910-AI37) to make the DSUR mandatory was published in December 2022 but had not been finalized as of early 2025. Canada and the UK additionally require a region-specific information section under the 2021 Health Canada/MHRA guidance that describes signal evaluation and review in greater detail than the base ICH E2F format.

Regulatory responsibility for the DSUR rests with the sponsor under ICH E2F. In CRO arrangements, preparation is typically delegated to the CRO's medical writing and pharmacovigilance teams, but accountability for accuracy and timely submission does not transfer. Where multiple parties co-develop a compound, explicit responsibility agreements are required and separate DSURs may be necessary. Compressing aggregation, drafting, cross-functional review, QC, and submission into a 60-day window is the operational core of DSUR preparation, and most missed deadlines trace to late data extracts, inconsistent IB versions, or unresolved literature questions rather than the writing itself.

Preparation challenges concentrate in three areas: (1) aggregating safety data across multiple safety databases, CTMS instances, and CRO platforms with reconciled cumulative exposure calculations; (2) maintaining IB consistency, since the IB in effect at the start of the cycle defines expectedness and any mid-cycle IB update must be reflected in line listing classifications; and (3) completing serial cross-functional reviews (medical writing, safety physician, regulatory affairs, biostatistics, quality) inside the 60-day window. AI-assisted drafting can populate standard sections, extract and tabulate data, run IB consistency checks, and track checklist completion, but the overall safety assessment and benefit-risk conclusion remain the domain of experienced pharmacovigilance professionals.